Compare INTA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | VERA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | 2021 | 2021 |
| Metric | INTA | VERA |
|---|---|---|
| Price | $23.29 | $42.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $50.25 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.7M | 967.8K |
| Earning Date | 02-03-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $543,341,000.00 | N/A |
| Revenue This Year | $15.66 | N/A |
| Revenue Next Year | $13.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.84 | N/A |
| 52 Week Low | $20.76 | $18.53 |
| 52 Week High | $77.74 | $56.05 |
| Indicator | INTA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 19.23 | 44.21 |
| Support Level | $22.88 | $41.46 |
| Resistance Level | $26.32 | $44.96 |
| Average True Range (ATR) | 2.19 | 2.19 |
| MACD | -0.63 | -0.27 |
| Stochastic Oscillator | 14.56 | 28.81 |
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.